15th World Bispecific Summit 2024

  • 02-04 Oct 2024
  • Colonnade Hotel, Boston, MA, United States

Description

The 15th World Bispecific Summit 2024 covers topics such as:

  • Novel Formats of Multispecifics Seminar
  • Targeting Complex Biology by Innovative Biologics – A Review of Bispecific Formats, Novel Platforms, Automation & Computation
  • Considering Geometry & Spatial Design & How it Impacts Bispecific Functionality
  • Implications of Synonymous Gene Recoding Strategies on the Properties of Therapeutic Proteins
  • Immune Cell Modulators with Multispecifics Seminar
  • Characterization of T-Cell Recruiting Bispecific Antibody Formats by Newly Developed Analytical Methods
  • Immuno-STATs: Soluble PHLA Engagers of TCRs of Tumor-Specific T Cells – Maximizing Efficacy Via Selectivity & Safety
  • Bispecific & Beyond: Bringing a Bispecific to the Clinic & Adding Valency for Specificity & Co-Stimulation
  • Creating Cancer-Specific Neoantigens with Covalent Inhibitors That Can Be Targeted by T-cell Engagers
  • Modular Discovery of Cis-Acting Bispecifics, Bispecific ADC & Multifunctional Drug Candidates
  • Development of mRNA-Encoded Bispecific Antibodies for Cancer Immunotherapy Via the RiboMab® Platform
  • Engineering Trispecific T-cell Engagers to Address Biological Challenges in the Treatment of Solid Tumors
  • Bispecific, Trispecific & Multispecific Antibodies: Where We Are So Far
  • A Review of the Bispecific Landscape: The Past, The Present & The Future of Biologics
  • Bispecific T-Cell Engagers in Oncology
  • Data Driven Approaches for Informed Target Discovery & Validation
  • Construction of a MET Bispecific Antibody Drug Conjugate
  • Navigating the Unknown: Strategies for Assessing Bispecific Targets Without a Clear Mechanism of Action
  • Optimizing Translation into the Clinic to Maximize Bispecific Therapeutic Indexes
  • Antibody-Based Multi-functional Modalities – Challenges & Opportunities
  • The Modular PreTarg-it Platform Enables RIT for Hardto-Treat Cancers by Significantly Improved Therapeutic Indexes
  • Selectivity & Specificity: Role of Immunology & Tumor Biology in Identifying Promising Bispecific Antibody Targets
  • Overcoming T-cell Engager Challenges Using Albumin Biomolecular Multispecific Designs & Patient Stratification
  • Maskless T-cell Engaging Bispecific Antibodies Designed for Proteolytic Activation in The Tumor Microenvironment
  • High Throughput SPR Characterization of Multispecific Antibodies – Capabilities & Workflow Approaches Advancing Discovery
  • Balancing Affinity vs. Avidity to Mitigate Toxicity & Safety Challenges
  • Safety of Bispecific Antibodies, ADCs and CAR-T cells
  • High Specificity OmniAb Antibodies for Bispecific Applications
  • Minimizing Toxicity While Preserving Efficacy Through Micellar Encapsulation of T-cell Engaging Bi-specific Antibodies
  • Revolutionizing Therapeutic Development: Forward-Planning Clinical Stage Assets: Setting Your Bispecific Pipeline Up for Clinical Success
  • Looking to Satisfy the Growing Demand of Capacity & Capabilities for Biologics
  • Bispecifics As the Next Go-To Oncology Therapeutic: Competing with CAR-T
  • Bispecific Antibodies Redirect Synthetic Agonistic Receptor Modified T Cells Against Melanoma
  • Overtaking CAR-T & ADCs in Relapsed/Refractory Multiple Myeloma Treatments: How Do Bispecific Therapies Fare in the Clinic?
  • Case Studies of Successful Bispecific Target Discovery & Validation
  • GEM-DIMERs™: Merging Multiple Clinically Relevant Antibodies Into a Single Molecule for Enhanced Functionality
  • Adopting a Biomarker-Driven Bispecific Antibody Development (details TBC)
  • Supercharging the Efficacy of Bispecific Treatments Through Combinations
  • Antibody-Based Multi-functional Modalities – Challenges & Opportunities
  • Targeted Therapies & Combinatorial Approaches for the Enhancement of Anti-Tumor T Cell Responses
  • Realizing the Full Potential of Bispecific Antibodies: Combinations & Treatments Beyond Oncology
  • Strong Anti-Tumor Activities by Simultaneously Activating CD40 & Inhibiting PD-1 Signalling In Vitro & In Vivo
  • Beyond Oncology: PEGylated T-cell Engager for Autoimmune Diseases
  • Challenges in Bispecific Antibody Development – Resistance Mechanisms & Patient Heterogeneity

Venue

  • Colonnade Hotel , 120 Huntington Avenue , Boston, Massachusetts, United States

More Details

Prices:
2499-5696 US Dollar (Estimated)
Organizer:
Hanson Wade
Website:

Future Events

Past Events

Important

Please, check "Summit - World Multispecifics" official website for possible changes, before making any traveling arrangements

Event Categories

Health & Medicine: Pharma
Science: Life Sciences & Biology

Other Events with Similar Categories

Other Events with Similar Location or Organizer

Featured Conferences & Exhibitions